IP Library Granted Patent US 7,402,662
Granted Patent B2
US 7,402,662 · App. 11/374,231 · Granted Jul 22, 2008

Antibody molecules specific to human tumor necrosis factor alpha

Assignee: UCB Pharma S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,662
App. No.
11/374,231
Granted
Jul 22, 2008
Kind
B2
Abstract

There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα.

Claims (2)

1. A compound comprising a modified Fab fragment comprising a heavy chain having the sequence comprising SEQ ID NO:130 and a light chain having the sequence comprising SEQ ID NO:128, further comprising a lysyl-maleimide group attached to a cysteine residue at the C-terminal end of the heavy chain, wherein each amino group of the lysyl residue has covalently linked to it a methoxypoly(ethyleneglycol) residue as shown in FIG. 13 , where n is about 420.

2. A compound comprising an antibody molecule having specificity for human TNFα, having a light chain comprising the sequence given in SEQ ID NO:128 and a heavy chain comprising the sequence given in SEQ ID NO:130, having attached to one of the cysteine residues at the C-terminal end of the heavy chain a lysyl-maleimide group wherein each amino group of the lysyl residue has covalently linked to it a methoxypoly(ethyleneglycol) residue having a molecular weight of about 20,000 Da.

Assignments (8)
CHANGE OF NAME Recorded May 10, 2011
From: CELLTECH CHIROSCIENCE LIMITED
To: CELLTECH R&D LIMITED
Reel/Frame 026256/0910 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2011
From: UCB S.A.
To: UCB PHARMA S.A.
Reel/Frame 026257/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2011
From: ATHWAL, DILJEER SINGH; BROWN, DEREK THOMAS; WEIR, ANDREW NEIL CHARLES; POPPLEWELL, ANDREW GEORGE; CHAPMAN, ANDREW PAUL; KING, DAVID JOHN
To: CELLTECH CHIROSCIENCE LIMITED
Reel/Frame 026257/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2011
From: CELLTECH R&D LIMITED
To: UCB S.A.
Reel/Frame 026257/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2008
From: CELLTECH R&D LIMITED
To: UCB S.A.
Reel/Frame 020415/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2008
From: UCB S.A.
To: UCB PHARMA S.A.
Reel/Frame 020416/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2006
From: ATHWAL, DILJEET SINGH; BROWN, DEREK THOMAS; WEIR, ANDREW NEIL CHARLES; POPPLEWELL, ANDREW GEORGE; CHAPMAN, ANDREW PAUL; KING, DAVID JOHN
To: CELLTECH CHIROSCIENCE LIMITED
Reel/Frame 018583/0514 →
CHANGE OF NAME Recorded Dec 4, 2006
From: CELLTECH CHIROSCIENCE LIMITED
To: CELLTECH R&D LIMITED
Reel/Frame 018589/0501 →
Priority Claims (1)
GB 0013810.7 · Jun 6, 2000 · national
Continuity (3)
Continuation 0994955900 · Sep 10, 2001
Continuation 0987522100 · Jun 6, 2001
Related Publication 20060233800A1 · Oct 19, 2006